Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | — |
Patient took 3 of the 4 Vivotif capsules on three consecutive days; Case reference number US-BN-2025-001790 is a spontaneous case initially received from other health care professional on 11-Nov-2025 via Bavarian Nordic (reference number: CASE-000684) and concerns a male patient of an unspecified age. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient administered 3 of the 4 Vivotif capsules on three consecutive days (batch number and expiration date: not reported), at an unknown doses, site or route of administration for an unknown indication (explicitly coded as, 'Inappropriate schedule of vaccine administered'). The patient then skipped one day between the 3rd and 4th capsule of Vivotif. At the time of initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A male patient of an unspecified age administered 3 of the 4 Vivotif capsules on three consecutive days for an unknown indication, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of an unspecified age administered 3 of the 4 Vivotif capsules on three consecutive days for an unknown indication, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None